幼年接种疫苗的垂直与水平HIV感染年轻成人的风疹抗体及对血清学阴性者加强接种的应答
前瞻性队列研究纳入垂直HIV感染96人、水平HIV感染69人、既往接种风疹疫苗的健康对照93人及有风疹病史的健康对照20人,检测风疹抗体。垂直HIV感染者的风疹血清阳性率及抗体水平显著低于水平HIV感染者。血清学阴性者接种额外MMR疫苗后,48人中40人(83.3%)产生应答。
要点
- 垂直HIV感染者风疹血清阳性率32.3%,显著低于水平HIV感染者的65.5%。
- 垂直HIV感染者风疹抗体中位数4.3 IU/mL,显著低于水平HIV感染者的21.1 IU/mL。
- 血清学阴性者接种额外MMR疫苗后,48人中40人(83.3%)产生应答。
核心结论
- 随着垂直HIV感染者进入青春期和成年期,评估疫苗抗体可识别可能受益于额外疫苗剂量者。
研究设计与样本
- 前瞻性队列研究,纳入垂直HIV-1感染96人、水平HIV-1感染69人、既往接种风疹疫苗的健康对照93人及有风疹病史的健康对照20人。
- 采集血样以ELISA检测风疹抗体,抗体高于10 IU/mL视为具有保护性。
- 血清学阴性者接种额外MMR疫苗剂量,并至少30天后检测。
主要发现
- 既往风疹疫苗接种至研究入组时间在垂直HIV感染组、水平HIV感染组和接种疫苗健康对照组分别为16年、11年和11年(p=0.428)。
- 研究入组时,垂直HIV感染组与水平HIV感染组CD4 T细胞中位数分别为613和614 cells/mm3(p=0.599),接受抗逆转录病毒治疗比例分别为93.8%和98.6%(p=0.135)。
- 垂直HIV感染组病毒学抑制比例63.5%,低于水平HIV感染组的85.5%(p<0.001)。
- 垂直HIV感染组风疹血清阳性率32.3%,低于水平HIV感染组的65.5%;风疹抗体中位数4.3 IU/mL,低于水平HIV感染组的21.1 IU/mL(p<0.001)。
- 末次风疹疫苗接种至研究入组的时间间隔与风疹血清阴性率增加相关,每增加一年血清阴性几率高7%。
临床怎么用
- 作者认为,随着垂直HIV感染者进入青春期和成年期,评估疫苗抗体可识别可能受益于额外疫苗剂量者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Very limited data are available on the persistence of rubella antibodies in vertically HIV-infected individuals who were vaccinated early in life. METHODS: Prospective, cohort study on 4 groups of patients: 96 vertically HIV-1-infected individuals (v-HIV), 69 horizontally HIV-1-infected individuals (h-HIV), 93 healthy controls previously vaccinated for rubella (vac-CON) and 20 healthy controls with history of rubella disease (dis-CON). A blood sample was collected and rubella antibodies were analyzed by ELISA. Rubella antibodies above 10 IU/mL were considered protective. Individuals with seronegative results were offered an extra MMR vaccine dose and were tested at least 30 days afterwards. RESULTS: Time since previous rubella vaccination was similar in v-HIV, h-HIV and vac-CON (16, 11 and 11 years; p = 0.428). v-HIV and h-HIV were also comparable regarding median CD4 T cells (613 and 614 cells/mm3; p = 0.599) and percentage on ART (93.8% and 98.6%; p = 0.135) at study entry. v-HIV had less individuals on virological suppression (63.5%) compared to 85.5% in h-HIV (p < 0.001). Rubella seropositivity and antibodies were significantly lower in v-HIV compared to h-HIV (32.3% vs 65.5%, 4.3 IU/mL vs 21.1 IU/mL; p < 0.001). Time interval between the last rubella vaccine dose and study entry was associated with an increase of rubella seronegativity, with a 7% higher chance of seronegativity for each one-year increase. After an extra MMR dose, 40 out of 48 (83.3%) seronegative individuals responded, with no significant difference among groups considering rubella seropositivity and antibody levels. CONCLUSION: As vertically HIV-infected individuals reach adolescence and adulthood, assessment of vaccine antibodies can identify those who might benefit from an extra vaccine dose.
引用
- Araujo BC, Simakawa R, Munhoz LG, et al. Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results. Vaccine. 2022. PMID: 35717264. doi:10.1016/j.vaccine.2022.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。